These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. The plasminogen content of commercial preparations and of normal donor plasma in relation to the plasmin content of the 1st international plasmin reference preparation. Wolf P Thromb Haemost; 1979 Aug; 42(2):582-95. PubMed ID: 159512 [TBL] [Abstract][Full Text] [Related]
27. Crystal structure of the catalytic domain of human plasmin complexed with streptokinase. Wang X; Lin X; Loy JA; Tang J; Zhang XC Science; 1998 Sep; 281(5383):1662-5. PubMed ID: 9733510 [TBL] [Abstract][Full Text] [Related]
29. Interaction of a group A Streptococcus within human plasma results in assembly of a surface plasminogen activator that contributes to occupancy of surface plasmin-binding structures. D'Costa SS; Boyle MD Microb Pathog; 1998 Jun; 24(6):341-9. PubMed ID: 9632538 [TBL] [Abstract][Full Text] [Related]
30. Plasminogen activation at low temperatures in plasma samples containing therapeutic concentrations of tissue-type plasminogen activator or other thrombolytic agents. Rijken DC; Seifried E; Barrett-Bergshoeff MM; Dooijewaard G Thromb Haemost; 1990 Aug; 64(1):47-52. PubMed ID: 2125758 [TBL] [Abstract][Full Text] [Related]
31. Efficacy of plasmin, microplasmin, and streptokinase-plasmin complex for the in vitro degradation of fibronectin and laminin- implications for vitreoretinal surgery. Hermel M; Dailey W; Hartzer MK Curr Eye Res; 2010 May; 35(5):419-24. PubMed ID: 20450255 [TBL] [Abstract][Full Text] [Related]
32. Acylated plasminogen-streptokinase activator complex: a new approach to thrombolytic therapy. Crabbe SJ; Grimm AM; Hopkins LE Pharmacotherapy; 1990; 10(2):115-26. PubMed ID: 2140889 [TBL] [Abstract][Full Text] [Related]
33. Late activation of the fibrinolytic system in myocardial infarction treated with thrombolytic therapy. Influence of the coronary anatomical substrate. Salvioni A; Perego GB; Marenzi G; Lauri G; Giraldi F; Grazi S; Guazzi MD Eur Heart J; 1996 Feb; 17(2):230-6. PubMed ID: 8732376 [TBL] [Abstract][Full Text] [Related]
34. Influence of coagulation on the activation of plasminogen by streptokinase and urokinase. Takada A; Urano T; Takada Y Thromb Haemost; 1979 Oct; 42(3):901-8. PubMed ID: 505405 [TBL] [Abstract][Full Text] [Related]
35. Studies on the effect of plasminogen activator on the interaction between alpha 2-macroglobulin and plasmin. Toki N; Takasugi S; Sumi H; Yamura T Thromb Haemost; 1978 Oct; 40(2):377-86. PubMed ID: 83685 [TBL] [Abstract][Full Text] [Related]
36. Different effect of 5,6-trans-prostaglandin E2 on plasminogen activation by urokinase and streptokinase. Urano T; Ikeda C; Shimokawa M; Kinoshita T Biochim Biophys Acta; 1994 Apr; 1205(2):258-61. PubMed ID: 8155706 [TBL] [Abstract][Full Text] [Related]
37. [Mechanism of thrombolytic enzymes]. Matsuo O Rinsho Ketsueki; 1993 Apr; 34(4):395-402. PubMed ID: 8510325 [TBL] [Abstract][Full Text] [Related]
38. [Compared activation of kinin system by streptokinase and urokinase "in vitro" and during thrombolytic treatments (author's transl)]. Migne J; Vedrine Y; Conard J; Samama M Pathol Biol (Paris); 1977 Dec; 25 Suppl():42-7. PubMed ID: 149942 [No Abstract] [Full Text] [Related]
39. [Degradation of streptokinase and the catalytic properties of the plasmin-streptokinase complex]. Hrynenko TV; Makohonenko IeM; Iusova OI; Cederholm-Williams SA Ukr Biokhim Zh (1999); 2002; 74(3):50-7. PubMed ID: 12916237 [TBL] [Abstract][Full Text] [Related]
40. Modification of acyl-plasmin-streptokinase complex with polyethylene glycol. Reduction of sensitivity to neutralizing antibody. Tomiya N; Watanabe K; Awaya J; Kurono M; Fujii S FEBS Lett; 1985 Nov; 193(1):44-8. PubMed ID: 2933274 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]